Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 1
2007 1
2008 1
2009 1
2010 3
2011 1
2012 1
2013 2
2014 4
2015 15
2016 18
2017 17
2018 13
2019 8
2020 21
2021 24
2022 21
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial.
Stahl A, Sukgen EA, Wu WC, Lepore D, Nakanishi H, Mazela J, Moshfeghi DM, Vitti R, Athanikar A, Chu K, Iveli P, Zhao F, Schmelter T, Leal S, Köfüncü E, Azuma N; FIREFLEYE Study Group. Stahl A, et al. JAMA. 2022 Jul 26;328(4):348-359. doi: 10.1001/jama.2022.10564. JAMA. 2022. PMID: 35881122 Free PMC article. Clinical Trial.
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2023 Dec 28:S0161-6420(23)00933-8. doi: 10.1016/j.ophtha.2023.12.026. Online ahead of print. Ophthalmology. 2023. PMID: 38158159 Free article.
Sildenafil in ophthalmology: An update.
Arora S, Surakiatchanukul T, Arora T, Cagini C, Lupidi M, Chhablani J. Arora S, et al. Among authors: cagini c. Surv Ophthalmol. 2022 Mar-Apr;67(2):463-487. doi: 10.1016/j.survophthal.2021.06.004. Epub 2021 Jun 25. Surv Ophthalmol. 2022. PMID: 34175342 Review.
The choroidal rupture: current concepts and insights.
Lupidi M, Muzi A, Castellucci G, Kalra G, Piccolino FC, Chhablani J, Cagini C. Lupidi M, et al. Among authors: cagini c. Surv Ophthalmol. 2021 Sep-Oct;66(5):761-770. doi: 10.1016/j.survophthal.2021.01.014. Epub 2021 Feb 2. Surv Ophthalmol. 2021. PMID: 33545177 Review.
Associations of Alzheimer's disease with macular degeneration.
Biscetti L, Luchetti E, Vergaro A, Menduno P, Cagini C, Parnetti L. Biscetti L, et al. Among authors: cagini c. Front Biosci (Elite Ed). 2017 Jan 1;9(1):174-191. doi: 10.2741/e794. Front Biosci (Elite Ed). 2017. PMID: 27814598 Free article. Review.
Central serous chorioretinopathy imaging biomarkers.
Singh SR, Iovino C, Zur D, Masarwa D, Iglicki M, Gujar R, Lupidi M, Maltsev DS, Bousquet E, Bencheqroun M, Amoroso F, Lima LH, Padhy SK, Govindahari V, Chandra K, Souied EH, Rodriguez FJ, Daza LA, Rios HA, Cagini C, Peiretti E, Behar-Cohen F, Chhablani J. Singh SR, et al. Among authors: cagini c. Br J Ophthalmol. 2022 Apr;106(4):553-558. doi: 10.1136/bjophthalmol-2020-317422. Epub 2020 Dec 7. Br J Ophthalmol. 2022. PMID: 33288526
Canaloplasty: Current Value in the Management of Glaucoma.
Cagini C, Peruzzi C, Fiore T, Spadea L, Lippera M, Lippera S. Cagini C, et al. J Ophthalmol. 2016;2016:7080475. doi: 10.1155/2016/7080475. Epub 2016 Apr 30. J Ophthalmol. 2016. PMID: 27239337 Free PMC article. Review.
132 results